|
Market Closed -
Nasdaq
00:00:00 10/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.480 USD | -3.88% |
|
-9.82% | +15.89% |
| 09-08 | Veru Advances Oral Sabizabulin into Planned Phase 2 Clinical Trial for Daraxonrasib Resistant Metastatic Pancreatic Cancer | CI |
| 08-10 | Veru Inc., Q3 2026 Earnings Call, Aug 10, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- VERU Stock
- Consensus Veru Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
